- Home
- NGNE vs LNKB Comparison
NGNE vs LNKB Comparison
Compare NGNE & LNKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- LNKB
- Stock Information
- Founded
- NGNE 2003
- LNKB 2018
- Country
- NGNE United States
- LNKB United States
- Employees
- NGNE N/A
- LNKB N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- LNKB
- Sector
- NGNE Health Care
- LNKB
- Exchange
- NGNE Nasdaq
- LNKB Nasdaq
- Market Cap
- NGNE 325.3M
- LNKB 277.1M
- IPO Year
- NGNE N/A
- LNKB N/A
- Fundamental
- Price
- NGNE $19.95
- LNKB $7.21
- Analyst Decision
- NGNE Strong Buy
- LNKB Strong Buy
- Analyst Count
- NGNE 7
- LNKB 1
- Target Price
- NGNE $41.86
- LNKB $9.00
- AVG Volume (30 Days)
- NGNE 113.3K
- LNKB 39.1K
- Earning Date
- NGNE 08-11-2025
- LNKB 10-27-2025
- Dividend Yield
- NGNE N/A
- LNKB 4.16%
- EPS Growth
- NGNE N/A
- LNKB N/A
- EPS
- NGNE N/A
- LNKB 1.01
- Revenue
- NGNE N/A
- LNKB $121,982,000.00
- Revenue This Year
- NGNE N/A
- LNKB $18.26
- Revenue Next Year
- NGNE N/A
- LNKB N/A
- P/E Ratio
- NGNE N/A
- LNKB $7.14
- Revenue Growth
- NGNE N/A
- LNKB 79.01
- 52 Week Low
- NGNE $6.88
- LNKB $6.00
- 52 Week High
- NGNE $74.49
- LNKB $7.98
- Technical
- Relative Strength Index (RSI)
- NGNE 48.86
- LNKB 50.32
- Support Level
- NGNE $18.00
- LNKB $7.12
- Resistance Level
- NGNE $19.93
- LNKB $7.46
- Average True Range (ATR)
- NGNE 1.03
- LNKB 0.19
- MACD
- NGNE 0.01
- LNKB -0.00
- Stochastic Oscillator
- NGNE 55.71
- LNKB 41.42
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.